mediluxreferencecyberknife

Cyberknife

Prostate Cancer

References:

1. Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu, Taylor Murray and Michael J. Thun. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.

2. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.

3. Gerber HD et al. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 269(1): 61-64, 1993.

4. Chodak GW et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 (4): 242-248, 1994.

5. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.

6. Kupelian PA et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20(16): 3376-3385, 2002.

7. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.

8. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358-1367.

9. Leandri et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Uro. 1992 Mar; 47(3 Pt. 2): 883-7.

10. Badani KK, Kaul S, Menon M. Evolution of robotic radical prostatectomy: assessment after 2766 procedures. Cancer 2007;110:1951-1958.

11. Madeb R, Golijanin D, Knopf J, et al. Patient-reported validated functional outcome after extraperitoneal robotic-assisted nerve-sparing radical prostatectomy. Jsls 2007;11:443-448.

12. Patel VR, Thaly R, Shah K. Robotic radical prostatectomy: outcomes of 500 cases. BJU Int 2007;99:1109-1112.

13. Bagshaw MA, Kaplan ID, Cox RC. Prostate cancer. Radiation therapy for localized disease. Cancer 1993;71:939-952.

14. Ray GR et al. Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience. 1973. J Urol 167: 990-998, 2002.

15. Hanks GE et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54(2); 427-435, 2002.

16. Chuba PJ, Moughan J, Forman JD, et al. The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys 2001;50:325-334.

17. Anderson PR et al. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy. Cancer 89(12): 2565-2569, 2000.

18. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-1604.

19. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31-40.

20. Blasko JC, Grimm PD, Sylsvester JE, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273-278.

21. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.

22. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005;61:1306-1316.

23. Demanes D, Altieri G, Barnaba M, et al. High dose rate (HDR) monotherapy is equivalent to combined HDR brachytherapy and external beam radiation therapy (EBRT) for early prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:S351.

24. Schour L., High Dose Rate Monotherapy for Prostate Cancer Int. J Radiat Oncol Biol Phys 63(Supplement 1) S315, 2005.

25. Eulau, SM., High dose rate 192Itidium brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 years Int J Radiat Oncol Biol Phys 48: 149, 2000.

26. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171:1098-1104.

27. Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008;70:1588-1597.

28. Hara W, Patel D, Pawlicki T, et al. Hypofractionated stereotactic radiotherapy for prostate cancer: early results. Int J Radiat Oncol Biol Phys 2006;66:S324-325.

29. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565.

30. Shaida N, Malone PR. Open versus laparoscopic radical prostatectomy. The case for open radical prostatectomy. Ann R Coll Surg Engl 2007;89:108-110; discussion 108.

31. Olsson LE, Salomon L, Nadu A, et al. Prospective patient-reported continence after laparoscopic radical prostatectomy. Urology 2001;58:570-572.

32. Menon M, Shrivastava A, Kaul S, et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol 2007;51:648-657; discussion 657-648.

Lung Cancer

References:

1. U.S. Center for Disease Control and Prevention

2. American Cancer Society, “Cancer Facts & Figures, 2008”

3. Korst, R.J., Ginsberg, R.J., Ailawadi, M., Bains, M.S., Downey, R.J., Jr., Rusch, V.W. and Stover, D., Lobectomy improves ventilatory function in selected patients with severe COPD, Ann Thorac Surg, 66 (1998) 898-902.

4. Dominioni, L., Imperatori, A., Rovera, F., Ochetti, A., Torrigiotti, G. and Paolucci, M., Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening, Cancer, 89 (2000) 2334-44.

5. Flehinger, B.J., Kimmel, M. and Melamed, M.R., The effect of surgical treatment on survival from early lung cancer. Implications for screening, Chest, 101 (1992) 1013-8.

6. .Pennathur, A., Abbas, G., Christie, N., Landreneau, R. and Luketich, J.D., Video assisted thoracoscopic surgery and lobectomy, sublobar resection, radiofrequency ablation, and stereotactic radiosurgery: advances and controversies in the management of early stage non-small cell lung cancer, Curr Opin Pulm Med, 13 (2007) 267-70.

7. West, D., Rashid, S. and Dunning, J., Does video-assisted thoracoscopic lobectomy produce equal cancer clearance compared to open lobectomy for non-small cell carcinoma of the lung?, Interact Cardiovasc Thorac Surg, 6 (2007) 110-6.

8. Ginsberg, R.J. and Rubinstein, L.V., Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group, Ann Thorac Surg, 60 (1995) 615-22; discussion 622-3.

9. Martini, N., Bains, M.S., Burt, M.E., Zakowski, M.F., McCormack, P., Rusch, V.W. and Ginsberg, R.J., Incidence of local recurrence and second primary tumors in resected stage I lung cancer, J Thorac Cardiovasc Surg, 109 (1995) 120-9.

10. Dosoretz, D.E., Katin, M.J., Blitzer, P.H., Rubenstein, J.H., Salenius, S., Rashid, M., Dosani, R.A., Mestas, G., Siegel, A.D., Chadha, T.T. and et al., Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies, Int J Radiat Oncol Biol Phys, 24 (1992) 3-9.

11. Haffty, B.G., Goldberg, N.B., Gerstley, J., Fischer, D.B. and Peschel, R.E., Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 15 (1988) 69-73.

12. Sibley, G.S., Jamieson, T.A., Marks, L.B., Anscher, M.S. and Prosnitz, L.R., Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience, Int J Radiat Oncol Biol Phys, 40 (1998) 149-54.

13. Dosoretz, D.E., Galmarini, D., Rubenstein, J.H., Katin, M.J., Blitzer, P.H., Salenius, S.A., Dosani, R.A., Rashid, M., Mestas, G., Hannan, S.E. and et al., Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication, Int J Radiat Oncol Biol Phys, 27 (1993) 507-16.

14. Sibley, G.S., Jamieson, T.A., Marks, L.B., Anscher, M.S. and Prosnitz, L.R., Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience, Int J Radiat Oncol Biol Phys, 40 (1998) 149-54.

15. Yorke, E.D., Jackson, A., Rosenzweig, K.E., Braban, L., Leibel, S.A. and Ling, C.C., Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study, Int J Radiat Oncol Biol Phys, 63 (2005) 672-82.

16. Rosenzweig, K.E., Fox, J.L., Yorke, E., Amols, H., Jackson, A., Rusch, V., Kris, M.G., Ling, C.C. and Leibel, S.A., Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma, Cancer, 103 (2005) 2118-27.

17. Baumann, P., Nyman, J., Lax, I., Friesland, S., Hoyer, M., Rehn Ericsson, S., Johansson, K.A., Ekberg, L., Morhed, E., Paludan, M., Wittgren, L., Blomgren, H. and Lewensohn, R., Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries, Acta Oncol, 45 (2006) 787-95.

18. Fritz, P., Kraus, H.J., Muhlnickel, W., Hammer, U., Dolken, W., Engel-Riedel, W., Chemaissani, A. and Stoelben, E., Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases, Radiat Oncol, 1 (2006) 30.

19. Onishi, H., Araki, T., Shirato, H., Nagata, Y., Hiraoka, M., Gomi, K., Yamashita, T., Niibe, Y., Karasawa, K., Hayakawa, K., Takai, Y., Kimura, T., Hirokawa, Y., Takeda, A., Ouchi, A., Hareyama, M., Kokubo, M., Hara, R., Itami, J. and Yamada, K., Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study, Cancer, 101 (2004) 1623-31.

20. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670

21. Miyamoto, T., Baba, M., Yamamoto, N., Koto, M., Sugawara, T., Yashiro, T., Kadono, K., Ezawa, H., Tsujii, H., Mizoe, J. E., Yoshikawa, K., Kandatsu, S., and Fujisawa, T. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int.J.Radiat.Oncol.Biol.Phys, 67[3], 750-758. 2007.

22. Pisters, K.M., Evans, W.K., Azzoli, C.G., Kris, M.G., Smith, C.A., Desch, C.E., Somerfield, M.R., Brouwers, M.C., Darling, G., Ellis, P.M., Gaspar, L.E., Pass, H.I., Spigel, D.R., Strawn, J.R., Ung, Y.C. and Shepherd, F.A., Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline, J Clin Oncol, 25 (2007) 5506-18.

Brain Cancer

References:

1. CBTRUS, Primary Brain Tumors in the United States Statistical Report 1998-2002. 2006, Central Brain Tumor Registry of the United States. (http://www.cbtrus.org/)

2. Khuntia, D., et al., Whole-brain radiotherapy in the management of brain metastasis.

J Clin Oncol, 2006. 24(8): p. 1295-304.

3. Eichler, A.F. and S.R. Plotkin, Brain metastases. Curr Treat Options Neurol, 2008. 10(4): p. 308-14.

4. Andrews, D.W., Current neurosurgical management of brain metastases. Semin Oncol, 2008. 35(2): p. 100-7.

5. Black, P., A. Golby, and M. Johnson, The emerging field of neurosurgical oncology: novel techniques to optimize outcomes and minimize mishaps. Clin Neurosurg, 2007. 54: p. 36-46.

6. Tsao, M.N., et al., Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev, 2006. 3: p. CD003869.

7. Leksell, L., The stereotaxic method and radiosurgery of the brain. Acta Chir Scand, 1951. 102(4): p. 316-9.

8. Leksell, L., Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry, 1983. 46(9): p. 797-803.

9. Adler, J.R., Jr., et al., Toward an expanded view of radiosurgery. Neurosurgery, 2004. 55(6): p. 1374-6.

10. Naff, N.J., CyberKnife Radiosurgery in Neurosurgical Practice. Neurosurg Q, 2007. 17(4): p. 273-282.

11. Hara, W., S.G. Soltys, and I.C. Gibbs, CyberKnife robotic radiosurgery system for tumor treatment. Expert Rev Anticancer Ther, 2007. 7(11): p. 1507-15.

12. Chang, S.D., The CyberKnife: Potential in Patients with Cranial and Spinal Tumors. Am J Cancer, 2005. 4(6): p. 383-393.

Spinal Cancer

References:

1. Simmons, E.D. and Y. Zheng, Vertebral tumors: surgical versus nonsurgical treatment. Clin Orthop Relat Res, 2006. 443: p. 233-47.

2. Klimo P.Jr., S.M.H., Surgical Management of Spinal Metastases. The Oncologist, 2004. 9: p. 1880196.

3. Mut, M., D. Schiff, and M.E. Shaffrey, Metastasis to nervous system: spinal epidural and intramedullary metastases. J Neurooncol, 2005. 75(1): p. 43-56.

4. van den Hout, W.B., et al., Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst, 2003. 95(3): p. 222-9.

5. Ryu, S.I., et al., Image-guided hypo-fractionated stereotactic radiosurgery to spinal lesions. Neurosurgery, 2001. 49(4): p. 838-46.

6. Muacevic, A., et al., Technical description, phantom accuracy, and clinical feasibility for single-session lung radiosurgery using robotic image-guided real-time respiratory tumor tracking. Technol Cancer Res Treat, 2007. 6(4): p. 321-8.

7. Ho, A.K., et al., A study of the accuracy of cyberknife spinal radiosurgery using skeletal structure tracking. Neurosurgery, 2007. 60(2 Suppl 1): p. ONS147-56; discussion ONS156.

Liver Cancer

References

1. American Cancer Society, “Cancer Facts & Figures, 2008”

2. GLOBOCAN 2002 database, International Agency for Research on Cancer (ed). Lyon, France, 2002. http://www-dep.iarc.fr/globocan/database.htm

3. Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65: 1104-1110

4. Blum HE. Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 129-145

5. Fong, Y; Blumgart, LH; Cohen, AM. Surgical Treatment of Colorectal Metastases to the Liver. CA Cancer J Clin 1995; 45: 50-62

6. Tsuzuki T, Sugioka A, Ueda M, Iida S, Kanai T, Yoshii H, Nakayasu K. Hepatic resection for hepatocellular carcinoma. Surgery 1990; 107: 511-520

7. Hawkins MA, Dawson LA Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006 Apr 15;106(8):1653-63.

8. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007;67:793-798.

9. Wada H, Takai Y, Nemoto K, et al. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004;58:1114-1120.

10. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006;45:831-837.

11. Wong KH, Dieterich S, Tang, J, and Cleary, K. Quantitative Measurement of CyberKnife Robotic Arm Steering. TechnolCancer ResTreat. 2007; 6[6], 589-594.

12. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008, 15(4):1008-1014.

13. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 2007, 12(12):1425-1432.

14. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P..Ann Surg Oncol. 2008 Apr;15(4):1008-14. Epub 2008 Jan 31

Pancreatic Cancer

References:

1. American Cancer Society, “Cancer Facts & Figures, 2008”.

2. GLOBOCAN 2002 database, International Agency for Research on Cancer (ed). Lyon, France, 2002. http://www-dep.iarc.fr/globocan/database.htm.

3. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management, Am Fam Physician. 2006;73:485-492.

4. Perman M, Bellairs EE, Wu X, and Schwade JG. Cancer of the Pancreas with Special Reference to Epidemiology & Radiosurgery. In Mould, F, ed. Robotic Radiosurgery Volume 1; The CyberKnife Society Press, 301-313, 2007.

5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, 1999.

6. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients, Ann Surg 221:721-731, 1995.

7. Mawdsley S, Hall M, Glynne-Jones R. Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil. Clin Oncol (R Coll Radiol) 14:308-312, 2002.

8. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 58: 1017-21, 2004.

9. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 63: 320-3, 2005.

10. Hoffelt, C. and Didolkar, M. Stereotactic Radiosurgery for Unresectable Adenocarcinoma of the Pancreas: Initial Experience at Sinai Hospital of Baltimore. In: Urschel HC, ed. Robotic Radiosurgery: Treating Tumors that Move with Respiration. Heidelbert: Springer-Verlag, 177-192, 2007.

Medilux Healthcare Limited is a specialised marketing company. We promote devices on the basis of the Manufacturers' representations as to quality and efficacy and where possible we provide additional information as to the conditions which may benefit from their use but we do not guarantee that they will be suitable or effective for all purchasers. We do not examine or diagnose patients or recommend treatments and where we promote medical services this is on an information-only basis. Patients contract directly with these providers and all clinical decisions are made by them alone.